BRAF and melanoma: The CombiNeo phase II trial evaluated dabrafenib and trametinib in 21 resectable IIIB-C or oligometastatic stage IV melanoma patients with BRAF mutations; patients were randomized to standard care (surgery and adjuvant therapy) or to neoadjuvant (4 weeks) and adjuvant therapy based on dabrafenib plus trametinib (44 weeks).